JP Morgan Comments on Potential Combination Of Valeant And Zoetis, Remains Overweight VRX and Neutral on ZTS
The bank sees Zoetis as an 'attractive, durable, cash-pay business to Valeant's portfolio' and that a deal would be minimal accretive to EPS in the next 12 months. However, the deal would bring benefits in the longer run by aiding multiple expansion. Synergies remain elusive to those trying to identify them
Latest Ratings for VRX
|Nov 2016||Morgan Stanley||Maintains||Overweight|
|Nov 2016||Rodman & Renshaw||Downgrades||Buy||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.